» Articles » PMID: 15187130

Characterization of a Peptide Inhibitor of Janus Kinase 2 That Mimics Suppressor of Cytokine Signaling 1 Function

Overview
Journal J Immunol
Date 2004 Jun 10
PMID 15187130
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Positive and negative regulation of cytokines such as IFN-gamma are key to normal homeostatic function. Negative regulation of IFN-gamma in cells occurs via proteins called suppressors of cytokine signaling (SOCS)1 and -3. SOCS-1 inhibits IFN-gamma function by binding to the autophosphorylation site of the tyrosine kinase Janus kinase (JAK)2. We have developed a short 12-mer peptide, WLVFFVIFYFFR, that binds to the autophosphorylation site of JAK2, resulting in inhibition of its autophosphorylation as well as its phosphorylation of IFN-gamma receptor subunit IFNGR-1. The JAK2 tyrosine kinase inhibitor peptide (Tkip) did not bind to or inhibit tyrosine autophosphorylation of vascular endothelial growth factor receptor or phosphorylation of a substrate peptide by the protooncogene tyrosine kinase c-src. Tkip also inhibited epidermal growth factor receptor autophosphorylation, consistent with the fact that epidermal growth factor receptor is regulated by SOCS-1 and SOCS-3, similar to JAK2. Although Tkip binds to unphosphorylated JAK2 autophosphorylation site peptide, it binds significantly better to tyrosine-1007 phosphorylated JAK2 autophosphorylation site peptide. SOCS-1 only recognizes the JAK2 site in its phosphorylated state. Thus, Tkip recognizes the JAK2 autophosphorylation site similar to SOCS-1, but not precisely the same way. Consistent with inhibition of JAK2, Tkip inhibited the ability of IFN-gamma to induce an antiviral state as well as up-regulate MHC class I molecules on cells at a concentration of approximately 10 microM. This is similar to the K(d) of SOCS-3 for the erythropoietin receptor. These data represent a proof-of-concept demonstration of a peptide mimetic of SOCS-1 that regulates JAK2 tyrosine kinase function.

Citing Articles

Extracellular vesicle surface engineering with integrins (ITGAL & ITGB2) to specifically target ICAM-1-expressing endothelial cells.

Bergqvist M, Park K, Karimi N, Yu L, Lasser C, Lotvall J J Nanobiotechnology. 2025; 23(1):64.

PMID: 39885580 PMC: 11780982. DOI: 10.1186/s12951-025-03125-3.


Peptide discovery across the spectrum of neuroinflammation; microglia and astrocyte phenotypical targeting, mediation, and mechanistic understanding.

Benita B, Koss K Front Mol Neurosci. 2024; 17:1443985.

PMID: 39634607 PMC: 11616451. DOI: 10.3389/fnmol.2024.1443985.


SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation.

Morelli M, Madonna S, Albanesi C Front Immunol. 2024; 15:1393799.

PMID: 38975347 PMC: 11224294. DOI: 10.3389/fimmu.2024.1393799.


SOCS1 expression in cancer cells: potential roles in promoting antitumor immunity.

Ilangumaran S, Gui Y, Shukla A, Ramanathan S Front Immunol. 2024; 15:1362224.

PMID: 38415248 PMC: 10897024. DOI: 10.3389/fimmu.2024.1362224.


SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis.

Pandey R, Bakay M, Hakonarson H Front Immunol. 2023; 14:1271102.

PMID: 38022642 PMC: 10643230. DOI: 10.3389/fimmu.2023.1271102.